OverviewSuggest Edit

Intellia is a genome editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. This technology offers the potential to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. Intellia's combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

TypePublic
Founded2014
HQCambridge, US
Websiteintelliatx.com
Employee Ratings3

Latest Updates

Employees (est.) (Feb 2020)270(+28%)
Job Openings19
Revenue (FY, 2019)$43.1 M(+42%)
Share Price (May 2020)$17.5 (-1%)

Key People/Management at Intellia Therapeutics

John Leonard

John Leonard

President, Chief Executive Officer & Director
Eliana Clark

Eliana Clark

Senior Vice President, Technical Operations
Glenn Goddard

Glenn Goddard

Executive Vice President, Chief Financial Officer
José Rivera

José Rivera

Executive Vice President, General Counsel and Corporate Secretary
Fred Cohen

Fred Cohen

Director
Jean-François Formela

Jean-François Formela

Director
Show more

Intellia Therapeutics Office Locations

Intellia Therapeutics has an office in Cambridge
Cambridge, US (HQ)
40 Erie St #130
Show all (1)

Intellia Therapeutics Financials and Metrics

Intellia Therapeutics Revenue

Intellia Therapeutics's revenue was reported to be $43.10 m in FY, 2019
USD

Revenue (Q1, 2020)

12.9m

Net income (Q1, 2020)

(31.8m)

EBIT (Q1, 2020)

(33.0m)

Market capitalization (28-May-2020)

900.2m

Closing stock price (28-May-2020)

17.5

Cash (31-Mar-2020)

81.0m

EV

843.6m
Intellia Therapeutics's current market capitalization is $900.2 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

30.4m43.1m

Cost of goods sold

Gross profit

30.4m43.1m

Gross profit Margin, %

100%100%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

7.7m7.4m10.4m11.1m10.6m12.9m

Cost of goods sold

Gross profit

10.4m

Gross profit Margin, %

100%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

273.1m340.7m58.9m57.2m

Accounts Receivable

6.5m10.5m7.5m4.6m

Prepaid Expenses

3.7m3.4m5.1m

Inventories

1.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.6b)(67.5m)(85.3m)(99.5m)

Depreciation and Amortization

3.0k3.0m4.5m

Inventories

(285.0k)

Accounts Payable

163.0k(488.0k)232.0k1.9m
USDY, 2020

EV/EBIT

-25.5 x

EV/CFO

-21.9 x

Revenue/Employee

47.8k

Financial Leverage

1.3 x
Show all financial metrics

Intellia Therapeutics Online and Social Media Presence

Embed Graph

Intellia Therapeutics News and Updates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fou…

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results

CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fou…

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update

CAMBRIDGE, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present fourth quarter and full-year 2019 financial results and op…

Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference

CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, is presenting new data from two of its development programs at Keystone…

Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones

CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today provided an update on recent progress and the Company’s …

Intellia Therapeutics Announces Third Quarter 2019 Financial Results

CAMBRIDGE, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), reported operational highlights and financial results for the third quarter ended September 30, 2019.
Show more

Intellia Therapeutics Blogs

Perry Karsen

Perry Karsen John.Bissaillo… Tue, 03/10/2020 - 08:35 Member of the Compensation Committee Member of the Nominating and Corporate Governance Committee Perry Karsen Director Perry Karsen brings decades of successful executive leadership and board experience to his…

Intellia Therapeutics to Present at Evercore ISI 2nd Annual HealthCONx Conference

CAMBRIDGE, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the Evercore ISI 2 nd Annual HealthCONx Conference on

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2019 Earnings and Company Update

CAMBRIDGE, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2019 results and operational highlights in

Intellia Therapeutics Announces Presentations at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc . (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced one oral presentation and four poster

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conferences in

Arbitration Decision Affirms Intellia Therapeutics’ Interpretation of Licensing Agreement with Caribou Biosciences on the CRISPR/Cas9 Technology

Interim Award concluded all technology in dispute was exclusively licensed to Intellia   Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Show more

Intellia Therapeutics Frequently Asked Questions

  • When was Intellia Therapeutics founded?

    Intellia Therapeutics was founded in 2014.

  • Who are Intellia Therapeutics key executives?

    Intellia Therapeutics's key executives are John Leonard, Eliana Clark and Glenn Goddard.

  • How many employees does Intellia Therapeutics have?

    Intellia Therapeutics has 270 employees.

  • What is Intellia Therapeutics revenue?

    Latest Intellia Therapeutics annual revenue is $43.1 m.

  • What is Intellia Therapeutics revenue per employee?

    Latest Intellia Therapeutics revenue per employee is $159.6 k.

  • Who are Intellia Therapeutics competitors?

    Competitors of Intellia Therapeutics include 4D Molecular Therapeutics, Applied Viromics and Nemesis Bioscience.

  • Where is Intellia Therapeutics headquarters?

    Intellia Therapeutics headquarters is located at 40 Erie St #130, Cambridge.

  • Where are Intellia Therapeutics offices?

    Intellia Therapeutics has an office in Cambridge.

  • How many offices does Intellia Therapeutics have?

    Intellia Therapeutics has 1 office.